Related Experiment Video
Updated: Aug 8, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Phospholipase A2 activating protein induces tumor regression
D H Goddard1, J S Bomalaski, M A Clark
1Dept. of Medicine, Long Island College Hospital, Brooklyn, New York 11201, USA.
Drug News & Perspectives
|December 24, 2004
Summary
This study explores PLAP (placental alkaline phosphatase) as a novel cancer therapy. PLAP demonstrated significant tumor regression and increased survival in animal models, suggesting its potential in cancer treatment.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- The eicosanoid pathway and pro-inflammatory lipids modulate cancer growth.
- Inflammation and immune responses play roles in immune surveillance against tumors.
- Placental alkaline phosphatase (PLAP) is a pro-inflammatory agent with immune-modulating capacity.
Purpose of the Study:
- To investigate the potential of PLAP as a therapeutic agent for cancer.
- To explore the role of PLAP in cancer therapy by leveraging its pro-inflammatory and immune-modulating properties.
Main Methods:
- PLAP's pro-inflammatory properties were elucidated through various approaches.
- Tumor regression was assessed in an animal air pouch model of glioma after PLAP treatment.
- Life expectancy was evaluated in animal models with Lewis lung cancer and MTVL breast tumors treated with PEG-PLAP.
Main Results:
- A single PLAP treatment led to significant tumor regression in a glioma model within 72 hours.
- PEG-PLAP treatment increased the life expectancy of animals with Lewis lung cancer.
- Preliminary studies indicated a similar increase in life expectancy for mice with MTVL breast tumors treated with PLAP.
Conclusions:
- PLAP exhibits significant anti-tumor effects in preclinical models.
- PLAP demonstrates promise as a potential therapeutic agent for various cancers.
- Further research into PLAP for cancer therapy is warranted.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...